Incyte recorded net income of $158.2 million, basic net income per share of $0.82 and diluted net income per share of $0.80 for the 3 months ended March 31, 2025, compared to net income of $169.5 million in the corresponding period in 2024.

10-QQuarterly reportFiled Apr 29, 2025Period of report Mar 31, 2025Summary published (UTC) Oct 11, 2026

Key points

AI summary

Incyte recorded net income of $158.2 million, basic net income per share of $0.82 and diluted net income per share of $0.80 for the 3 months ended March 31, 2025, compared to net income of $169.5 million in the corresponding period in 2024.
Incyte said the increase in JAKAFI product revenues for Q1 2025 was comprised of a volume increase of $98.7 million and a price increase of $38.9 million, citing an increase in paid demand of 10% and the impact of less de-stocking of 7% as factors.
Incyte brought a lawsuit against the U.S. Centers for Medicare and Medicaid Services alleging that CMS's regulation on the definition of "line extension" treats OPZELURA as a line extension of JAKAFI, and said it accrued approximately $145.4 million within accrued and other current liabilities on the condensed consolidated balance sheet as of March 31, 2025 relating to the incremental rebates that would be owed were OPZELURA considered a line extension of JAKAFI.
The company said net cash provided by operating activities for Q1 2025 was $266.1 million (compared to $218.8 million for Q1 2024) and cash, cash equivalents and marketable securities as of March 31, 2025 were $2.4 billion.

Key figures

Quarter ended March 31, 2025

Revenue: $1.1B
Operating income: $205M
Net income: $158M
EPS: $0.80
Operating cash flow: $266M

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Q1 2025 Net Income and Net Income Per Share

Incyte recorded net income of $158.2 million, basic net income per share of $0.82 and diluted net income per share of $0.80 for the 3 months ended March 31, 2025, compared to net income of $169.5 million in the corresponding period in 2024.

Source · Based on the MD&A text of the filing

JAKAFI Revenue Increase Composition

Incyte said the increase in JAKAFI product revenues for Q1 2025 was comprised of a volume increase of $98.7 million and a price increase of $38.9 million, citing an increase in paid demand of 10% and the impact of less de-stocking of 7% as factors.

Source · Based on the MD&A text of the filing

OPZELURA Line Extension Litigation and Accrued Amount

Incyte brought a lawsuit against the U.S. Centers for Medicare and Medicaid Services alleging that CMS's regulation on the definition of "line extension" treats OPZELURA as a line extension of JAKAFI, and said it accrued approximately $145.4 million within accrued and other current liabilities on the condensed consolidated balance sheet as of March 31, 2025 relating to the incremental rebates that would be owed were OPZELURA considered a line extension of JAKAFI.

Source · Based on the MD&A text of the filing

Operating Cash Flow and Cash and Marketable Securities

The company said net cash provided by operating activities for Q1 2025 was $266.1 million (compared to $218.8 million for Q1 2024) and cash, cash equivalents and marketable securities as of March 31, 2025 were $2.4 billion.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗